Gamaryl-VM Forte Tablet SR is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (1000mg), and Voglibose (0.3mg), designed to effectively manage type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily reduces hepatic glucose production and improves insulin sensitivity, enhancing peripheral glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestines, preventing postprandial blood sugar spikes. The sustained-release formulation ensures a gradual and prolonged release of the active ingredients, promoting better glycemic control with reduced dosing frequency and minimizing gastrointestinal side effects commonly associated with Metformin. Gamaryl-VM Forte is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal blood sugar regulation. It is essential to use this medication under medical supervision, with regular monitoring of blood glucose levels and renal function. Lifestyle modifications, including diet and exercise, should accompany pharmacotherapy for maximum benefit. Patients should be advised about potential side effects such as hypoglycemia, gastrointestinal discomfort, and the importance of adherence to prescribed dosages to prevent complications.